About Apcintex
Apcintex is a company based in Cambridge (United Kingdom) founded in 2014 was acquired by Centessa Pharmaceuticals in February 2021. Apcintex has raised $17.5 million across 1 funding round from investors including Cambridge Enterprise, Centessa Pharmaceuticals and Touchstone Innovations. The company has 2 employees as of December 31, 2021. Apcintex operates in a competitive market with competitors including Editas Medicine, GBT, LogicBio, Modus Therapeutics and Kedrion, among others.
- Headquarter Cambridge, United Kingdom
- Employees 2 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Apcintex Limited
- Date of Incorporation 16 Jun, 2014
- Jurisdiction ALTRINCHAM, CHESHIRE, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17.5 M (USD)
in 1 rounds
-
Latest Funding Round
$17.5 M (USD), Series A
Feb 02, 2017
-
Investors
Cambridge Enterprise
& 3 more
-
Employee Count
2
as on Dec 31, 2021
-
Acquired by
Centessa Pharmaceuticals
(Feb 18, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Apcintex
Apcintex has successfully raised a total of $17.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $17.5 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Apcintex
Apcintex has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Cambridge Enterprise, Centessa Pharmaceuticals and Touchstone Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life science focused VC firm investing in geographies such as Europe and the US
|
Locked | Locked | Locked | |
|
Provider of intellectual property management and technology consulting services
|
Locked | Locked | Locked | |
|
Creates, builds and invests in pioneering technology companies spun-out from Univs Cambridge, Oxford, and UCL
|
Locked | Locked | Locked |
Investor details for Apcintex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Apcintex
Investment portfolio details for Apcintex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Apcintex
Detailed financials for Apcintex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Apcintex Comparisons
Peer comparison for Apcintex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Apcintex
Apcintex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, GBT, LogicBio, Modus Therapeutics and Kedrion, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Small molecules are developed for sickle cell disease treatment.
|
|
| Locked | Locked | Locked |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| Locked | Locked | Locked |
Polysaccharide-based drug for Sickle Cell Disease treatment is developed.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| Locked | Locked | Locked |
Drug candidates for rare diseases are acquired, developed, and commercialized.
|
Detailed competitors of Apcintex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Apcintex
Complete news archive for Apcintex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apcintex
Apcintex was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Apcintex is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Apcintex is a funded company, having raised a total of $17.5M across 1 funding round to date.
As of Dec 31, 2021, the latest employee count at Apcintex is 2.
Based on the work of Professor Jim Huntington (Cambridge Institute for Medical Research) and Dr Trevor Baglin (Cambridge University Hospitals), Apcintex has developed a new treatment that seeks to turn down the activity of a key natural anticoagulant pathway to produce normal blood clotting in patients with haemophilia. This means that the drug could potentially treat patients with all types of haemophilia, including those who develop antibodies to replacement factors.
Apcintex's top competitors include GBT, Editas Medicine and Kedrion.
Apcintex has 4 investors. Key investors include Cambridge Enterprise, Centessa Pharmaceuticals, Touchstone Innovations, and Medicxi.